<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047137</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0013</org_study_id>
    <nct_id>NCT01047137</nct_id>
  </id_info>
  <brief_title>Response of Urticaria to Stress Intervention</brief_title>
  <official_title>Effect of Psychological Stress Intervention on Chronic Urticaria Activity and Immune Dysregulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have shown a relationship between psychological stress and chronic urticaria
      (hives). The primary objective of this study is to evaluate the effect psychological stress
      intervention has on chronic urticaria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As many patients with chronic urticaria display heightened levels of stress before and/or
      after the onset of the urticaria, the purpose of this study is to evaluate the effect of
      psychological stress intervention on chronic urticaria. Intervention group participants will
      meet with a psychiatry resident once a week for six consecutive weeks to be educated on
      psychological stress intervention techniques. Control group participants will meet with a
      psychiatry resident once a week for six consecutive weeks for general supportive therapy,
      which will not provide psychological stress intervention. All participants will complete a
      packet of psychological and dermatological questionnaires before the first session with the
      psychiatry resident and one week after the final session. All participants will record daily
      1) their urticaria symptoms and 2) the type and number of antihistamines taken. Blood and
      saliva samples will be collected before the first session and one week after completion of
      the final session to compare the levels of stress hormones and cytokines in order to evaluate
      an effect on immune dysregulation.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients enrolled. A pilot study variation of this study was done instead.
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect psychological stress intervention has on chronic urticaria as measured by the Urticaria Activity Score</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the pre-intervention and post-intervention symptoms as determined by a packet of psychological and dermatological questionnaires.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pre- and post-intervention cytokine and stress hormone levels.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of as-needed antihistamines used as the study progresses.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Urticaria</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychological Stress Intervention</intervention_name>
    <description>Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>General Supportive Therapy</intervention_name>
    <description>There is no focus on stress intervention.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females age 18-64 years who are inadequately controlled on H1 and/or
             H2-blocker therapy for chronic urticaria

          -  The Urticaria Activity Score must have a score of at least 2 (one point from each of
             the two categories: number of hives and severity of pruritus).

        Exclusion Criteria:

          -  Urticaria secondary to vasculitis

          -  Use of prednisone, hydroxychloroquine, cyclosporine, or a tricyclic antidepressant
             (except Doxepin) within the 30 days prior to enrollment

          -  A history of anaphylaxis

          -  Non-controlled or debilitating chronic diseases (poorly controlled diabetes or
             congestive heart failure)

          -  An immune system disorder

          -  Deranged stress hormone level (for example, Cushing's disease)

          -  Ongoing omalizumab therapy

          -  Nocturnal employment (which would effect study measures, such as cortisol levels).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Tole, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center Div of Allergy and Immunology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gailen D Marshall, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Mississippi Medical Center Div of Allergy and Immunology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim L Gratz, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Mississippi Medical Center Div of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM; British Society for Allergy and Clinical Immunology (BSACI). BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007 May;37(5):631-50.</citation>
    <PMID>17456211</PMID>
  </reference>
  <reference>
    <citation>Sperber J, Shaw J, Bruce S. Psychological components and the role of adjunct interventions in chronic idiopathic urticaria. Psychother Psychosom. 1989;51(3):135-41.</citation>
    <PMID>2636418</PMID>
  </reference>
  <reference>
    <citation>Papadopoulou N, Kalogeromitros D, Staurianeas NG, Tiblalexi D, Theoharides TC. Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. J Invest Dermatol. 2005 Nov;125(5):952-5.</citation>
    <PMID>16297195</PMID>
  </reference>
  <reference>
    <citation>Yang HY, Sun CC, Wu YC, Wang JD. Stress, insomnia, and chronic idiopathic urticaria--a case-control study. J Formos Med Assoc. 2005 Apr;104(4):254-63.</citation>
    <PMID>15909063</PMID>
  </reference>
  <reference>
    <citation>Ozkan M, Oflaz SB, Kocaman N, Ozseker F, Gelincik A, Büyüköztürk S, Ozkan S, Colakoğlu B. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2007 Jul;99(1):29-33.</citation>
    <PMID>17650826</PMID>
  </reference>
  <reference>
    <citation>Silvares MR, Coelho KI, Dalben I, Lastória JC, Abbade LP. Sociodemographic and clinical characteristics, causal factors and evolution of a group of patients with chronic urticaria-angioedema. Sao Paulo Med J. 2007 Sep 6;125(5):281-5.</citation>
    <PMID>18094895</PMID>
  </reference>
  <reference>
    <citation>Berrino AM, Voltolini S, Fiaschi D, Pellegrini S, Bignardi D, Minale P, Troise C, Maura E. Chronic urticaria: importance of a medical-psychological approach. Eur Ann Allergy Clin Immunol. 2006 May;38(5):149-52.</citation>
    <PMID>17058846</PMID>
  </reference>
  <reference>
    <citation>Annesi-Maesano I, Beyer A, Marmouz F, Mathelier-Fusade P, Vervloet D, Bauchau V. Do patients with skin allergies have higher levels of anxiety than patients with allergic respiratory diseases? Results of a large-scale cross-sectional study in a French population. Br J Dermatol. 2006 Jun;154(6):1128-36.</citation>
    <PMID>16704645</PMID>
  </reference>
  <reference>
    <citation>Marshall GD. Neuroendocrine mechanisms of immune dysregulation: applications to allergy and asthma. Ann Allergy Asthma Immunol. 2004 Aug;93(2 Suppl 1):S11-7. Review.</citation>
    <PMID>15330008</PMID>
  </reference>
  <reference>
    <citation>Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96.</citation>
    <PMID>6668417</PMID>
  </reference>
  <reference>
    <citation>Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988 Jul;26(7):724-35.</citation>
    <PMID>3393032</PMID>
  </reference>
  <reference>
    <citation>Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.</citation>
    <PMID>8033378</PMID>
  </reference>
  <reference>
    <citation>Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, Kapp A, Kozel MM, Maurer M, Merk HF, Schäfer T, Simon D, Vena GA, Wedi B; EAACI/GA2LEN/EDF. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006 Mar;61(3):316-20. Review.</citation>
    <PMID>16436140</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urticaria</keyword>
  <keyword>Hives</keyword>
  <keyword>Stress</keyword>
  <keyword>Immune dysregulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

